본문 바로가기
KERD
논문KCI 등재

Systemic treatment for advanced urothelial cancer: an update on recent clinical trials and current treatment options

Jae Lyun Lee|Inkeun Park
대한내과학회 (The Korean Association Of Internal Medicine)|2020.07|The Korean Journal of Internal Medicine|제35권 제4호|pp. 834-853|DOI https://doi.org/10.3904/kjim.2020.204

2

조회

0

다운로드

0

인용

0

참고문헌

키워드

Drug therapyTherapeuticsImmunotherapyCarcinomatransitional cell
주제분류내과학

초록

After cisplatin-based chemotherapy became the standard treatment for metastatic urothelial cancer (mUC), very little progress has been made in the treatment landscape of this condition until recently. With increased knowledge about the molecular biology of mUC and advances in the field of cancer immunobiology, there has been an explosion in the number of clinical trials for mUC, and systemic treatment of mUC is rapidly changing. Despite the availability of several novel therapeutic agents, cisplatin-based cytotoxic chemotherapy remains the standard, first-line treatment option. Immune checkpoint inhibitors (ICIs), including programmed death-1 and programmed death ligand-1 inhibitors, are preferred second-line treatment options that are also used in first-line cisplatin-ineligible settings. For patients with actionable fibroblast growth factor receptor 2 (FGFR2) or FGFR3 genomic alterations, erdafitinib can be considered after platinum-based treatment. Enfortumab vedotin, a monoclonal antibody targeting nectin-4 conjugated to monomethyl auristatin E, has been approved for patients who do not respond to both cytotoxic chemotherapy and ICIs. In this review, we address the clinical trial data that have established the current standard treatments and ongoing clinical trials of various agents with different mechanisms as well as provide a brief overview of current practice guidelines and recommendations in patients with mUC.

Abstract

After cisplatin-based chemotherapy became the standard treatment for metastatic urothelial cancer (mUC), very little progress has been made in the treatment landscape of this condition until recently. With increased knowledge about the molecular biology of mUC and advances in the field of cancer immunobiology, there has been an explosion in the number of clinical trials for mUC, and systemic treatment of mUC is rapidly changing. Despite the availability of several novel therapeutic agents, cisplatin-based cytotoxic chemotherapy remains the standard, first-line treatment option. Immune checkpoint inhibitors (ICIs), including programmed death-1 and programmed death ligand-1 inhibitors, are preferred second-line treatment options that are also used in first-line cisplatin-ineligible settings. For patients with actionable fibroblast growth factor receptor 2 (FGFR2) or FGFR3 genomic alterations, erdafitinib can be considered after platinum-based treatment. Enfortumab vedotin, a monoclonal antibody targeting nectin-4 conjugated to monomethyl auristatin E, has been approved for patients who do not respond to both cytotoxic chemotherapy and ICIs. In this review, we address the clinical trial data that have established the current standard treatments and ongoing clinical trials of various agents with different mechanisms as well as provide a brief overview of current practice guidelines and recommendations in patients with mUC.

참고문헌 (140)

  1. Bray F, "Global cancer statistics 2018 : GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries", CA Cancer J Clin, 68, pp.394~424 (2018)
  2. Royce TJ, "Clinical characteristics and outcomes of nonurothelial cell carcinoma of the bladder : results from the National Cancer Data Base", Urol Oncol, 36, pp.78.e1~78.e12 (2018)
  3. Cumberbatch MGK, "Epidemiology of bladder cancer : a systematic review and contemporary update of risk factors in 2018", Eur Urol, 74, pp.784~795 (2018)
  4. Sternberg CN, "Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours", Eur J Cancer, 42, pp.50~54 (2006)
  5. von der Maase H, "Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer", J Clin Oncol, 23, pp.4602~4608 (2005)
  6. Abdollah F, "Incidence, survival and mortality rates of stage-specific bladder cancer in United States : a trend analysis", Cancer Epidemiol, 37, pp.219~225 (2013)
  7. Sternberg CN, "Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC)chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924", J Clin Oncol, 19, pp.2638~2646 (2001)
  8. von der Maase H, "Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer : results of a large, randomized, multinational, multicenter, phase III study", J Clin Oncol, 18, pp.3068~3077 (2000)
  9. Oliver RT, "A phase 2study of Cis-platinum in patients with recurrent bladder carcinoma. The London and Oxford Co-operative Urological Cancer Group", Br J Urol, 53, pp.444~447 (1981)
  10. Rossof AH, "Phase II evaluation of cis-dichlorodiammineplatinum(II)in advanced malignancies of the genitourinary and gynecologic organs : a Southwest Oncology Group Study", Cancer Treat Rep, 63, pp.1557~1564 (1979)
  11. Sternberg CN, "Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse", Cancer, 64, pp.2448~2458 (1989)
  12. Loehrer PJ Sr, "A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma : a cooperative group study", J Clin Oncol, 10, pp.1066~1073 (1992)
  13. Logothetis CJ, "A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors", J Clin Oncol, 8, pp.1050~1055 (1990)
  14. Stadler WM, "Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer", J Clin Oncol, 15, pp.3394~3398 (1997)
  15. Moore MJ, "Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer : a phase II trial of the National Cancer Institute of Canada Clinical Trials Group", J Clin Oncol, 17, pp.2876~2881 (1999)
  16. Soto Parra H, "Three-week versus four-week schedule of cisplatin and gemcitabine : results of a randomized phase II study", Ann Oncol, 13, pp.1080~1086 (2002)
  17. Als AB, "Gemcitabine and cisplatin in locally advanced and metastatic bladder cancer;3-or 4-week schedule", Acta Oncol, 47, pp.110~119 (2008)
  18. Roth BJ, "Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium : a phase II trial of the Eastern Cooperative Oncology Group", J Clin Oncol, 12, pp.2264~2270 (1994)
  19. de Wit R, "Docetaxel (Taxotere): an active agent in metastatic urothelial cancer; results of a phase II study in non-chemotherapy-pretreated patients", Br J Cancer, 78, pp.1342~1345 (1998)
  20. Bamias A, "Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group", J Clin Oncol, 22, pp.220~228 (2004)
  21. Sternberg CN, "Larotaxel with cisplatin in the first-line treatment of locally advanced", metastatic urothelial tract or bladder cancer:a randomized, active-controlled, phase III trial (CILAB), 2013, pp.85, 208~215
  22. Bellmunt J, "Randomized phase III study comparing paclitaxel", cisplatin, cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987, pp.J Clin Oncol, 2012[DOI]
  23. Bellmunt J, "Bladder cancer:ESMO Practice Guidelines for diagnosis, treatment and follow-up", Ann Oncol, 25(Suppl 3), pp.iii40~iii48 (2014)
  24. "Bladder cancer (version 3.2020)" (2020)[URL]
  25. "Guidelines on muscle-invasive and metastatic bladder cancer" (2020)[URL]
  26. Muggia FM, "Platinum antitumor complexes : 50 years since Barnett Rosenberg’s discovery", J Clin Oncol, 33, pp.4219~4226 (2015)
  27. Petrioli R, "Comparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent or metastatic bladder cancer patients. A randomized phase II study", Cancer, 77, pp.344~351 (1996)
  28. Dogliotti L, "Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium : results of a randomized phase 2 trial", Eur Urol, 52, pp.134~141 (2007)
  29. Galsky MD, "Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma", Ann Oncol, 23, pp.406~410 (2012)
  30. Galsky MD, "A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy", Lancet Oncol, 12, pp.211~214 (2011)
  31. Galsky MD, "Treatment of patients with metastatic urothelial cancer “unfit” for cisplatin-based chemotherapy", J Clin Oncol, 29, pp.2432~2438 (2011)
  32. De Santis M, "Randomized phase II", III trial assessing gemcitabine, carboplatin, pp.vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986, J Clin Oncol[DOI]
  33. Holmsten K, "Vinflunine", gemcitabine versus carboplatin, Eur J Cancer, pp.2020, 127[DOI]
  34. Park I, "Gemcitabine plus carboplatin versus gemcitabine plus oxaliplatin in cisplatin-unfit patients with advanced urothelial carcinoma: a randomised phase II study (COACH, KCSG GU10-16)", Eur J Cancer, 127, pp.183~190 (2020)
  35. De Santis M, "Vinflunine-gemcitabine versus vinflunine-carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomized phase II trial (JASINT1)", Ann Oncol, 27, pp.449~454 (2016)
  36. Bellmunt J, "A randomized phase II", III study of cabazitaxel versus vinflunine in metastatic or locally advanced transitional cell carcinoma of the urothelium (SECAVIN), 2017, pp.28, 1517~1522
  37. Papamichael D, "Phase II study of paclitaxel in pretreated patients with locally advanced", metastatic cancer of the bladder and ureter, 1997, pp.75, 606~607
  38. Joly F, "Do patients with advanced urothelial carcinoma benefit from weekly paclitaxel chemotherapy? A GETUG phase II study", Clin Genitourin Cancer, 7, pp.E28~E33 (2009)
  39. Beer TM, "Southwest Oncology Group phase II study of irinotecan in patients with advanced transitional cell carcinoma of the urothelium that progressed after platinum-based chemotherapy", Clin Genitourin Cancer, 6, pp.36~39 (2008)
  40. Lee JL, "Phase II study of a cremophor-free, polymeric micelle formulation of paclitaxel for patients with advanced urothelial cancer previously treated with gemcitabine and platinum", Invest New Drugs, 30, pp.1984~1990 (2012)
  41. Galsky MD, "Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma", Invest New Drugs, 25, pp.265~270 (2007)
  42. Witte RS, "Topotecan in previously treated advanced urothelial carcinoma : an ECOG phase II trial", Invest New Drugs, 16, pp.191~195 (1998)
  43. Witte RS, "Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma", J Clin Oncol, 15, pp.589~593 (1997)
  44. Sweeney CJ, "Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium", J Clin Oncol, 24, pp.3451~3457 (2006)
  45. Vaughn DJ, "Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer", J Clin Oncol, 20, pp.937~940 (2002)
  46. Ko YJ, "Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma : a single group, multicentre, phase 2 study", Lancet Oncol, 14, pp.769~776 (2013)
  47. Dreicer R, "Phase 2 trial of epothilone B analog BMS-247550 (ixabepilone) in advanced carcinoma of the urothelium (E3800): a trial of the Eastern Cooperative Oncology Group", Cancer, 110, pp.759~763 (2007)
  48. Bellmunt J, "Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy", Ann Oncol, 24, pp.1466~1472 (2013)
  49. Bellmunt J, "Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract", J Clin Oncol, 27, pp.4454~4461 (2009)
  50. Bellmunt J, "Pembrolizumab as second-line therapy for advanced urothelial carcinoma", N Engl J Med, 376, pp.1015~1026 (2017)
  51. Powles T, "Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma(IMvigor211) : a multicentre, open-label, phase 3 randomised controlled trial", Lancet, 391, pp.748~757 (2018)
  52. Sharma P, "Nivolumab in metastatic urothelial carcinoma after platinum therapy(CheckMate 275) : a multicentre, single-arm, phase 2 trial", Lancet Oncol, 18, pp.312~322 (2017)
  53. Powles T, "Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma : updated results from a phase 1", 2open-label study, 2017, pp.3, e172411~
  54. Patel MR, "Avelumab in metastatic urothelial carcinoma after platinum failure(JAVELIN Solid Tumor) : pooled results from two expansion cohorts of an open-label, phase 1 trial", Lancet Oncol, 19, pp.51~64 (2018)
  55. Fradet Y, "Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer : results of >2 years of follow-up", Ann Oncol, 30, pp.970~976 (2019)
  56. Van der Heijden MS, "918P:Atezolizumab (atezo) vs chemotherapy (chemo) in patients (pts) with platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): a long-term overall survival (OS) and safety update from the phase III IMvigor211study", Ann Oncol, 30(Suppl 5), pp.v365~v366 (2019)
  57. 허준영, "Atezolizumab in Patients with Pretreated Urothelial Cancer: A Korean Single-Center, Retrospective Study", Cancer Research and Treatment, 51(4), pp.1269~1274 (2019), 대한암학회
  58. Sternberg CN, "Primary results from SAUL, a multinational single-arm safety study of atezolizumab therapy for locally advanced or metastatic urothelial or nonurothelial carcinoma of the urinary tract", Eur Urol, 76, pp.73~81 (2019)
  59. Brahmer JR, "Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy : American Society of Clinical Oncology Clinical Practice Guideline", J Clin Oncol, 36, pp.1714~1768 (2018)
  60. Martins F, "Adverse effects of immune-checkpoint inhibitors : epidemiology, management and surveillance", Nat Rev Clin Oncol, 16, pp.563~580 (2019)
  61. Borcoman E, "Novel patterns of response under immunotherapy", Ann Oncol, 30, pp.385~396 (2019)
  62. Hwang I, "Hyperprogressive disease in patients with urothelial carcinoma or renal cell carcinoma treated with PD-1", PD-L1 inhibitors, 2020, pp.18, e122~e133
  63. Soria F, "Pseudoprogression and hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancer", World J Urol, 36, pp.1703~1709 (2018)
  64. Powles T, "Maintenance avelumab + best supportive care (BSC) versus BSC alone after platinum-based first-line (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN Bladder 100 phase III interim analysis", J Clin Oncol, 38(18 Suppl), pp.LBA1~ (2020)
  65. Balar AV, "Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma : a single-arm, multicentre, phase 2 trial", Lancet, 389, pp.67~76 (2017)
  66. Balar AV, "First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer(KEYNOTE-052) : a multicentre, single-arm, phase 2 study", Lancet Oncol, 18, pp.1483~1492 (2017)
  67. O’Donnell PH, "KEYNOTE-052 : Phase 2 study evaluating first-line pembrolizumab(pembro)in cisplatin-ineligible advanced urothelial cancer(UC) : updated response and survival results", J Clin Oncol, 37(15 Suppl), pp.4546~ (2019)
  68. Suzman DL, "FDA approval summary : atezolizumab or pembrolizumab for the treatment of patients with advanced urothelial carcinoma ineligible for cisplatin-containing chemotherapy", Oncologist, 24, pp.563~569 (2019)
  69. Galsky MD, "Atezolizumab with or without chemotherapy in metastatic urothelial cancer(IMvigor130) : a multicentre, randomised, placebo-controlled phase 3 trial", Lancet, 395, pp.1547~1557 (2020)
  70. "Update on phase III DANUBE trial for imfinzi and tremelimumab in unresectable, stage IV bladder cancer" (2020)[URL]
  71. Iyer G, "Prevalence and co-occurrence of actionable genomic alterations in highgrade bladder cancer", J Clin Oncol, 31, pp.3133~3140 (2013)
  72. Cancer Genome Atlas Research Network, "Comprehensive molecular characterization of urothelial bladder carcinoma", Nature, 507, pp.315~322 (2014)
  73. Ross JS, "Advanced urothelial carcinoma : next-generation sequencing reveals diverse genomic alterations and targets of therapy", Mod Pathol, 27, pp.271~280 (2014)
  74. Robertson AG, "Comprehensive molecular characterization of muscle-invasive bladder cancer", Cell, 171, pp.540~556 (2017)
  75. Sethakorn N, "Spectrum of genomic alterations in FGFR3 : current appraisal of the potential role of FGFR3 in advanced urothelial carcinoma", BJU Int, 118, pp.681~691 (2016)
  76. Carolyn D. Hurst, "Mutational landscape of non-muscle-invasive bladder cancer", Urologic Oncology: Seminars and Original Investigations (2018), Elsevier BV[DOI]
  77. Guancial EA, "FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder", Cancer Med, 3, pp.835~844 (2014)
  78. Dip N, "MiRNA in bladder carcinogenesis : a review", World J Clin Urol, 3, pp.238~248 (2014)
  79. Milowsky MI, "Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma", Eur J Cancer, 50, pp.3145~3152 (2014)
  80. Loriot Y, "Erdafitinib in locally advanced or metastatic urothelial carcinoma", N Engl J Med, 381, pp.338~348 (2019)
  81. Schuler M, "Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression : a phase 1 dose-escalation and dose-expansion study", Lancet Oncol, 20, pp.1454~1466 (2019)
  82. Quinn DI, "FORT-1: Phase II", III study of rogaratinib versus chemotherapy (CT) in patients (pts) with locally advanced or metastatic urothelial carcinoma (UC) selected based on FGFR1, J Clin Oncol, pp.2020, 38(6 Suppl)[DOI]
  83. Pal SK, "Efficacy of BGJ398, a fibroblast growth factor receptor 1-3 inhibitor, in patients with previously treated advanced urothelial carcinoma with FGFR3 alterations", Cancer Discov, 8, pp.812~821 (2018)
  84. Necchi A, "900P: Interim results of fight-201, a phase II, open-label, multicenter study of INCB054828 in patients (pts) with metastatic or surgically unresectable urothelial carcinoma (UC)harboring fibroblast growth factor (FGF)", FGF receptor (FGFR) genetic alterations (GA), 2018, pp.29(Suppl 8), viii319~viii320
  85. Mellado B, "Interim analysis of the fierce-21 phase 2 (P2) study of vofatamab (B-701), a selective inhibitor of FGFR3, as salvage therapy in metastatic urothelial carcinoma (mUC)", J Clin Oncol, 37(15Suppl), pp.4547~ (2019)
  86. Sweis RF, "Molecular drivers of the non-t-cell-inflamed tumor microenvironment in urothelial bladder cancer", Cancer Immunol Res, 4, pp.563~568 (2016)
  87. Palakurthi S, "The combined effect of FGFR inhibition and PD-1 blockade promotes tumor-intrinsic induction of antitumor immunity", Cancer Immunol Res, 7, pp.1457~1471 (2019)
  88. Siefker-Radtke AO, "FIERCE-22:Clinical activity of vofatamab (V) a FGFR3 selective inhibitor in combination with pembrolizumab (P) in WT metastatic urothelial carcinoma, preliminary analysis", J Clin Oncol, 37(15 Suppl), pp.4511~ (2019)
  89. Powles T, "902O : An adaptive, biomarker directed platform study in metastatic urothelial cancer(BISCAY)with durvalumab in combination with targeted therapies", Ann Oncol, 30(Suppl 5), pp.v356~v357 (2019)
  90. Grivas PD, "Urothelial carcinomas : a focus on human epidermal receptors signaling", Am J Transl Res, 3, pp.362~373 (2011)
  91. Petrylak DP, "Results of the Southwest Oncology Group phase II evaluation(study S0031)of ZD1839 for advanced transitional cell carcinoma of the urothelium", BJU Int, 105, pp.317~321 (2010)
  92. Philips GK, "A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102", Ann Oncol, 20, pp.1074~1079 (2009)
  93. Wong YN, "Phase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinoma", J Clin Oncol, 30, pp.3545~3551 (2012)
  94. Hussain M, "A randomized phase 2 trial of gemcitabine", cisplatin with or without cetuximab in patients with advanced urothelial carcinoma, 2014, pp.120, 2684~2693
  95. Wülfing C, "A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma", Cancer, 115, pp.2881~2890 (2009)
  96. Tang S, "Single arm phase II study of docetaxel and lapatinib in metastatic urothelial cancer : USC trial 4B-10-4", J Clin Oncol, 34(2 Suppl), pp.424~ (2016)
  97. Cerbone L, "Results from a phase I study of lapatinib with gemcitabine and cisplatin in advanced or metastatic bladder cancer: EORTC trial 30061", Oncology, 90, pp.21~28 (2016)
  98. Powles T, "Phase III, double-blind, randomized trial that compared maintenance lapatinib versus placebo after first-line chemotherapy in patients with human epidermal growth factor receptor 1", 2-positive metastatic bladder cancer, 2017, pp.35, 48~55
  99. Choudhury NJ, "Afatinib activity in platinum-refractory metastatic urothelial carcinoma in patients with ERBB alterations", J Clin Oncol, 34, pp.2165~2171 (2016)
  100. Hussain MH, "Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2", neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial, 2007, pp.25, 2218~2224
  101. Oudard S, "Multicentre randomised phase II trial of gemcitabine+platinum, with or without trastuzumab, in advanced or metastatic urothelial carcinoma overexpressing Her2", Eur J Cancer, 51, pp.45~54 (2015)
  102. Bryce AH, "Pertuzumab plus trastuzumab for HER2-positive metastatic urothelial cancer (mUC): preliminary data from MyPathway", J Clin Oncol, 35(6 Suppl), pp.348~ (2017)
  103. Fus LP, "Role of angiogenesis in urothelial bladder carcinoma", Cent European J Urol, 69, pp.258~263 (2016)
  104. Dreicer R, "Phase 2 trial of sorafenib in patients with advanced urothelial cancer : a trial of the Eastern Cooperative Oncology Group", Cancer, 115, pp.4090~4095 (2009)
  105. Bellmunt J, "Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy:baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity", Ann Oncol, 22, pp.2646~2653 (2011)
  106. Necchi A, "Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial", Lancet Oncol, 13, pp.810~816 (2012)
  107. Jones RJ, "Randomized phase II study investigating pazopanib versus weekly paclitaxel in relapsed or progressive urothelial cancer", J Clin Oncol, 35, pp.1770~1777 (2017)
  108. Apolo AB, "A phase II study of cabozantinib in patients (pts) with relapsed or refractory metastatic urothelial carcinoma (mUC)", J Clin Oncol, 34(15 Suppl), pp.4534~ (2016)
  109. Naik G, "A phase II trial of regorafenib for advanced urothelial cancer(aUC)following prior chemotherapy", J Clin Oncol, 38(6 Suppl), pp.498~ (2020)
  110. Galsky MD, "Gemcitabine, cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancer", Clin Genitourin Cancer, 11, pp.175~181 (2013)
  111. Choueiri TK, "Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer", J Clin Oncol, 30, pp.507~512 (2012)
  112. Narayanan S, "Phase II study of pazopanib and paclitaxel in patients with refractory urothelial cancer", Clin Genitourin Cancer, 14, pp.432~437 (2016)
  113. Petrylak DP, "Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial", Lancet, 390, pp.2266~2277 (2017)
  114. Petrylak DP, "Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3trial", Lancet Oncol, 21, pp.105~120 (2020)
  115. Rosenberg JE, "CALGB 90601(Alliance): randomized, double-blind, placebo-controlled phase III trial comparing gemcitabine and cisplatin with bevacizumab or placebo in patients with metastatic urothelial carcinoma", J Clin Oncol, 37(15 Suppl), pp.4503~ (2019)
  116. Zhu N, "Preclinical rationale and clinical efficacy of antiangiogenic therapy and immune checkpoint blockade combination therapy in urogenital tumors", J Cancer Res Clin Oncol, 145, pp.3021~3036 (2019)
  117. Birrer MJ, "Antibody-drug conjugate-based therapeutics : state of the science", J Natl Cancer Inst, 111, pp.538~549 (2019)
  118. Rosenberg JE, "Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1", programmed death ligand 1 therapy, 2019, pp.37, 2592~2600
  119. Mandai K, "Nectins and nectin-like molecules in development and disease", Curr Top Dev Biol, 112, pp.197~231 (2015)
  120. Challita-Eid PM, "Enfortumab vedotin antibody-drug conjugate targeting nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models", Cancer Res, 76, pp.3003~3013 (2016)
  121. Rosenberg JE, "Study EV-103 : preliminary durability results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma", J Clin Oncol, 38(6 Suppl), pp.441~ (2020)
  122. Trerotola M, "Upregulation of Trop-2 quantitatively stimulates human cancer growth", Oncogene, 32, pp.222~233 (2013)
  123. Avellini C, "The trophoblast cell surface antigen 2 and miR-125b axis in urothelial bladder cancer", Oncotarget, 8, pp.58642~58653 (2017)
  124. Tagawa ST, "Sacituzumab govitecan (IMMU-132) in patients with previously treated metastatic urothelial cancer (mUC): results from a phase I", II study, 2019, pp.37(7 Suppl), 354~
  125. Tagawa ST, "LBA55: Initial results from TROPHY-U-01: A phase II open-label study of sacituzumab govitecan in patients (Pts) with metastatic urothelial cancer (mUC) after failure of platinum-based regimens (PLT) or immunotherapy", Ann Oncol, 30(Suppl 5), pp.v890~v891 (2019)
  126. Yao X, "A novel humanized anti-HER2 antibody conjugated with MMAE exerts potent anti-tumor activity", Breast Cancer Res Treat, 153, pp.123~133 (2015)
  127. Sheng X, "A phase II study of RC48-ADC in HER2-positive patients with locally advanced or metastatic urothelial carcinoma", J Clin Oncol, 37(15Suppl), pp.4509~ (2019)
  128. "Trastuzumab deruxtecan with nivolumab in advanced breast and urothelial cancer" (2020)[URL]
  129. Al-Husseini MJ, "Trends in the incidence and mortality of transitional cell carcinoma of the bladder for the last four decades in the USA : a SEERbased analysis", BMC Cancer, 19, pp.46~ (2019)
  130. Repetto L, "Greater risks of chemotherapy toxicity in elderly patients with cancer", J Support Oncol, 1(4 Suppl 2), pp.18~24 (2003)
  131. Galsky MD, "Real-world effectiveness of chemotherapy in elderly patients with metastatic bladder cancer in the United States", Bladder Cancer, 4, pp.227~238 (2018)
  132. Mohile SG, "Do elderly patients have a worse outcome in response to platinum-based therapy for metastatic urothelial cancer", Nat Clin Pract Oncol, 2, pp.392~393 (2005)
  133. Hurria A, "Predicting chemotherapy toxicity in older adults with cancer : a prospective multicenter study", J Clin Oncol, 29, pp.3457~3465 (2011)
  134. Garg T, "Burden of multiple chronic conditions among patients with urological cancer", J Urol, 199, pp.543~550 (2018)
  135. Lee L, "Impact of comorbidity on chemotherapy use and outcomes in solid tumors : a systematic review", J Clin Oncol, 29, pp.106~117 (2011)
  136. Klapheke A, "Sociodemographic disparities in chemotherapy treatment and impact on survival among patients with metastatic bladder cancer", Urol Oncol, 36, pp.308.e19~ (2018)
  137. Johnson DB, "Immune checkpoint inhibitors in challenging populations", Cancer, 123, pp.1904~1911 (2017)
  138. Bajorin DF, "Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy", J Clin Oncol, 17, pp.3173~3181 (1999)
  139. Bellmunt J, "Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens", J Clin Oncol, 28, pp.1850~1855 (2010)
  140. Gupta S, "Defining “platinum-ineligible” patients with metastatic urothelial cancer (mUC)", J Clin Oncol, 37(7 Suppl), pp.451~ (2019)

관련 논문AI추천

Neoadjuvant Nivolumab plus Gemcitabine/Cisplatin Chemotherapy in Muscle-Invasive Urothelial Carcinoma of the Bladder박원, 송완, 권기영, 김찬교, 김홍식, 박세훈, 성현환, 정병창, 표홍렬, 홍정용, 홍주현대한암학회 · Cancer Research and Treatment2023 · 제55권 제2호Atezolizumab in Patients with Pretreated Urothelial Cancer: A Korean Single-Center, Retrospective Study강민용, 권기영, 김유진, 박세훈, 서성일, 성현환, 이수진, 이현무, 전성수, 전황균, 정병창, 허준영대한암학회 · Cancer Research and Treatment2019 · 제51권 제4호Use of Gemcitabine plus Carboplatin is Associated with Poor Outcomes in Urothelial Carcinoma Patients with Chronic Kidney Disease Stage 4-5김좌훈, 김형돈, 박인근, 윤신교, 이재련, 임현수, 정혜현대한암학회 · Cancer Research and Treatment2021 · 제53권 제4호Programmed cell death-ligand 1 assessment in urothelial carcinoma: prospect and limitation이규상, 최기영대한병리학회 · Journal of Pathology and Translational Medicine2021 · 제55권 제3호Adjuvant Chemotherapy for Upper Tract Urothelial Carcinoma: A Real-World, Retrospective Study송완, 박세훈, 성현환, 이준호, 임성희, 정병창, 정재훈대한암학회 · Cancer Research and Treatment2024 · 제56권 제3호Modified MVAC as a Second-Line Treatment for Patients with Metastatic Urothelial Carcinoma after Failure of Gemcitabine and Cisplatin Treatment천준, 강석호, 강성구, 김승태, 김열홍, 김준석, 박경화, 박영지, 서재홍, 성득제, 신상원, 오상철, 이정현, 최인근대한암학회 · Cancer Research and Treatment2014 · 제46권 제2호

이 간행물의 다른 논문 (35건)

Current laboratory diagnosis of coronavirus disease 2019Jihyang Lim, Jehoon Leepp. 741-748Consensus statement on coronary intervention during the coronavirus disease 19 pandemic: from the Korean Society of Interventional CardiologySong-Yi Kim, Sang-Hyun Kim, Jung-Won Suh, Bong-Ki Lee, Se Hun Kang, Sung Kee Ryu, Chang-Hwan Yoon, In-Ho Chae, Dong Heon Yang, Taek Kyu Park, Kwan Yong Lee, Sung Yun Lee, The Korean Society of Interventional Cardiology COVID-19 Task Force Te, 김원장pp. 749-757A cluster of tertiary transmissions of 2019 novel coronavirus (SARS-CoV-2) in the community from infectors with common cold symptomsMoon-Woo Seong, 이왕준, Wan Beom Park, Pyoeng Gyun Choe, Myoung-don Oh, Chang Kyung Kang, Nam Joong Kim, Sang-Joon Park, Jaegyun Limpp. 758-764Selecting coronavirus disease 2019 patients with negligible risk of progression: early experience from non-hospital isolation facility in KoreaNam Joong Kim, Wan Beom Park, Hyemin Jung, Eun Hwa Choi, Be Long Cho, Myoung-don Oh, Chang Kyung Kang, Pyoeng Gyun Choe, Sun Young Lee, Eun Kyo Kang, Boram Oh, Dahae Im, Hyo Yeon Lee, Min Sun Kimpp. 765-770Lung ultrasound for early diagnosis and severity assessment of pneumonia in patients with coronavirus disease 2019Young-Jae Cho, Hyunju Lee, Yunghee Lee, Joo Heung Yoon, Jongtak Jung, Sung Yoon Lim, Ji Young Park, Ho Il Yoon, Hong Bin Kim, Kyoung Un Park, Eu Suk Kim, 송경호pp. 771-781
원문 보기